
usd may pm et
summari lead manufactur gener pharmaceut produc broad rang tradit
specialti drug sold around world
price-to-earnings oper ep
oper typic drug develop risk includ
uncertainti stem program
regulatori approv process competitor challeng
market share signific legal risk also exist
on-going govern lawsuit investig relat
opioid sale practic alleg price-fix
gener risk partial off-set divers
portfolio product account
revenu sale come
outsid also think mitig risk
success histori develop complex
gener biosmilar
fiscal year end dec ep estim base cfra
oper earn histor earn report
cash dividend paid last year
past perform indic futur perform reli upon
analysi prepar equiti analyst
may stock trade
sale fell yoy driven drop
north america total drop
europ rest world grew
yoy sale declin big miss
vs consensu expect growth
maintain revenu guidanc
growth mid-point think
legitim reason believ
salvag growth
wixela less month sale
launch februari still drove
yoy growth largest categori
respiratori sale think growth
acceler later year wixela
sole gener multi-billion dollar advair
see rapid market share gain without
drop north america
smallest declin sinc
indic us gener deflat
fda gener applic hit
lowest level sinc europ
declin short-term view nearli
driven currenc translat
one-tim disrupt relat launch
new label track regul
share carri signific risk think
offer attract risk-reward profil
yield recent market cap use low
end estim firm biggest
challeng recent competit
pressur gener industri
issu mitig throughout
expect grow
long-term strength complex
increasingli shift focu
complex drug think begin pay
ramp gener
 biosimilar version multi-billion
dollar brand recent complex approv
compet oni peer includ
gcopaxon gadvair bneulasta bherceptin
ramp late-stag
asset take time larg invest
market think strategi pay
target price ep estim
-- histor forward price-to-earnings averag
due downstream consolid limit
price power risk view includ
revers sever gener deflat larg
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
chairman board
corpor overview develop licens manufactur market pharmaceut
primarili gener biosimilar varieti therapeut categori estim rank
twelfth among drug produc term total revenu largest -base
gener drug maker top five therapeut area term revenu central nervou system
anesthesia infecti diseas respiratori allergi gastroenterolog diabet
gener least total revenu
compani oper three segment north america gener total revenu
oper incom europ gener revenu oper incom rest
world gener revenu oper incom
market profil reach peak estim gross profit margin gener drug
industri fell nearli eight percentag point driven two key factor first annual fda gener
drug approv grew rapidli allow larg increas number
competitor produc typic gener drug second major retail pharmaci chain drug
wholesal band togeth purchas joint ventur increas negoti power gener
two factor combin produc sever drug price deflat result
sharp declin profit margin led sever gener competitor pull back industri
pullback turn driven signific slowdown fda gener applic applic preced
approv view six-month move averag applic fall march
declin recent peak januari cfra believ move averag gener
applic lead indic level competit gener on-going declin
point stabil competit condit gener maker view also support
fact fda gener approv fell peak gener price deflat
also soften estim yoy nearli yoy sever
think long-term trajectori gener sale growth posit industri experi
two import demand driver next five ten year includ rapid age develop
popul prime prescript util year particularli estim
babi boomer turn day rapidli expand middl class gain first-tim access
advanc health care pharmaceut emerg market nation like india china
corpor strategi mani gener drug maker equip target small-molecul brand
drug low barrier product thin margin exampl nine
compet gener viagra brand tablet fifteen differ gener lipitor brand tablet
unlik mani peer mostli produc simpler commodity-lik gener shift
busi toward large-molecul specialti drug biosimilar higher barrier entri due
complex regulatori approv manufactur requir estim commodity-lik
gener gener mylan gener sale amount fall
around compani ramp import new complex gener biosimilar
exampl recent success complex drug area includ gener copaxon inject
multipl sclerosi drug fda approv fulphila biosimilar neulasta anti-infect
inject cancer patient fda approv wixela inhub gener inhal asthma
brand advair fda approv multi-billion-dollar brand drug gener
biosimilar compet one gener provid greater valu crowd
commodity-lik gener space think compani robust pipelin continu complex drug
legal risk subject numer investig lawsuit govern
competitor year case sometim result larg legal settlement court
order damag may meaning impact abil make long-term
invest sustain growth pharmaceut busi march compani
defend number high profil case includ limit follow
name along numer drug manufactur distributor case relat
nation opioid crisi brought multipl government entiti name
defend class action suit relat price market epipen auto-injector
offic non- affili compani also name defend
epipen case respond inform request doj seek inform relat
price sale gener drug product fulli cooper
financi trend sale aid sever acquisit rose billion billion
repres three-year compound annual growth rate compound-annual-growth-rate howev sale fell
versu advers impact sever gener drug price deflat due intens
competit consolid downstream custom adjust pre-tax incom per share grew
declin repres three-year compound-annual-growth-rate
despit challeng environ gener drug maker recent year leverag
maintain safe though conserv level view ebita-to-interest
materi better peer-averag around
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
slightli under-valued usd
neutral sinc march technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
outlook pharmaceut sub-industri
next year posit reflect
strong novel drug approv activ food
 drug administr fda
-- posit brand drug
maker repres lion share
sub-industri market cap also expect
stabil gener profit margin
competit appear moder
modest growth overal prescript
banner year brand drug
fda new drug approv
repres continu recent surg
approv shatter previou
record-high approv set
year dwarf approv
mani new drug littl
competit provid tailwind
brand drug sale addit
novel drug approv rare
diseas receiv fda orphan statu
mean receiv seven year competit
exclus indic think
provid boost long-term brand
side sub-industri
outlook earn growth gener maker
posit closer neutral fda gener
approv total
mani
compet version gener enter
sever gener
price deflat becam norm profit margin
contract surprisingli number
firm announc asset divestitur exit
 gener industri
bright side remain gener
maker think exit start
impact gener approv
tick vs first materi
declin least six year also note
move averag gener
applic lead indic view
recent high march
think anoth sign mitig
competit help slow gener
deflat yoy februari
versu yoy worst deflat
month think moder gener
deflat allow stabil gener
profit margin year ahead
anoth boost gener maker
record year fda first-gener approv
first-gener typic enter market
materi lower price brand
counterpart temporari protect
gener competitor allow
quick market share gain accordingli
recent increas first-gener provid
revenu tailwind gener maker
bolster posit outlook
sub-industri expect continu
growth prescript volum year
ahead recent growth health-insur
popul driven solid
employ growth
view think gain continu
strong labor market pull peopl onto
employee-sponsor health plan
like seek fill prescript
also think wave babi boomer age
prime drug-util year support
long-term growth drug volum
drop
year-to-d march
pharma index rose gain
base index
five-year market price perform may
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
buy keep target
ep estim histor forward price-to-earnings averag due continu
headwind custom consolid risk govern investig
maintain ep estim believ
well-posit benefit potenti stabil gener drug
market recent peak around januari
six-month move averag fda gener drug applic fell novemb
latest data think result competitor scale back gener
oper could lead improv margin next two year
also expect gener industry-averag ep growth due strategi
focus gener biosimilar develop complex high-barri brand
drug sustain margin growth prospect adequ margin
safeti legal risk also exist view given histor low valuat
et cfra upgrad opinion share buy hold
keep target ep
estim histor averag forward price-to-earnings near see
continu challeng custom consolid risk multipl
govern investig maintain ep estim
initi share current low due struggl
last two year loss epipen price power gener price
deflat regulatori problem manufactur site think worst
day howev forecast improv profit margin
competit gener industri appear mitig fda gener
approv track decreas mark first declin sinc
think lead potenti turnaround industri earn
remain focus downturn mani
competitor pull back also see adequ margin safeti legal
risk given histor low valuat /colin scarola
analyst research note compani news
pm et cfra maintain opinion share gener drug maker
share firm involv gener drug includ teva
sharpli today follow
expans anti-trust lawsuit three firm subsidiari
alreadi name one defend relat on-going case origin
alleg illeg price fix drug may file
expand alleg defend firm involv mani drug
teva gener state claim without merit
plan defend alleg present materi risk
gener maker think risk much today
last week alleg relat case alreadi
underway sever year process like take sever year
conclus forward price-to-earnings multipl alreadi
long-term averag last week think risk alreadi price
pm et cfra maintain strong buy opinion share
lower target price ep estim
-- histor forward price-to-earnings averag due intens price pressur
gener drug drop ep estim
ep vs beat consensu revenu
declin yoy north america sale total europ
fall yoy respect due rapidly-grow sale new
complex gener biosimilar fail off-set declin commodity-lik
gener rest world sale total grew yoy strong growth
china sale growth well expect still think
revenu increas vs strong ramp gener advair
biosimilar neulasta sever new launch continu
think share attract valu low end guidanc
repres yield current market cap growth expect
long-term /colin scarola
pm et cfra rais sector overweight
marketweight cfra rais
sector overweight marketweight market valuat
expand sector trade discount histor averag cfra
find opportun within health care sector trade forward
price-to-earnings basi histor averag first quarter
compani health care sector beat sale
earn estim best perform index biotech
pharmaceut compani account market capit
sector drug pipelin approv time reduct activ make
industri attract care histori outperform
season slow period year may octob cfra
forecast sector like disappoint lindsey bell
et cfra maintain strong buy opinion share
lower target ep
estim -- histor forward price-to-earnings averag due price
headwind custom consolid drop ep estim
ep vs
consensu sale fell yoy driven declin north
america total lower volum continu gener price deflat
expect long-term invest complex gener biosimilar start
pay year howev forecast sale growth sever
new product ramp though requir increas
market spend gain share think hurt ep
ultim produc attract long-term growth market current
undervalu prospect view estim free
cash flow yield attract today market cap expect
grow substanti start /colin scarola
pm et cfra upgrad opinion share strong buy
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd
repres total revenu estim
fiscal year analyst estim earn
per share grow usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
